Timothy Hegeman, DO
Cardiovascular Disease · Colorado Springs, CONPI 1285990184
Payments from drug & device makers
What this record shows
Abbott accounts for 69.6% of it on its own, with 8 other manufacturers making up the rest.
Across 44 payments — averaging $98.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Amgen$341
- Heartflow, Inc.$244
- Amarin Pharma, Inc.$222
- Sanofi-aventis U.S. LLC$208
- Impulse Dynamics (USA) Inc.$128
- plus $178 from 3 others
Across 11 payments — averaging $25,304 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$278K
What the payments were for
- Travel & lodging$2,18050%
- Food & beverage$2,16450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 26 | $3,022 |
| Amgen | 4 | $341 |
| Heartflow, Inc. | 4 | $244 |
| Amarin Pharma, Inc. | 2 | $222 |
| Sanofi-aventis U.S. LLC | 2 | $208 |
| Impulse Dynamics (USA) Inc. | 1 | $128 |
| AstraZeneca | 1 | $66 |
| Kowa Pharmaceuticals America, Inc. | 1 | $59 |
| W. L. Gore & Associates, Inc. | 3 | $54 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$1,142
- TRICLIP$1,033
- OPTIMIZER$257
- Repatha$237
- Vascepa$222
- MitraClip$126
- DISEASE STATE$114
- FFRct$112
How this compares
$4,344 in reported general payments places this provider in the 70th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 469 | $599,184 |
| JardianceEmpagliflozin | 169 | $194,361 |
| EntrestoSacubitril/Valsartan | 104 | $131,086 |
| XareltoRivaroxaban | 83 | $109,453 |
| Repatha SureclickEvolocumab | 74 | $78,981 |
| FarxigaDapagliflozin Propanediol | 58 | $60,108 |
| Praluent PenAlirocumab | 13 | $16,734 |
| VascepaIcosapent Ethyl | 11 | $11,423 |
| Metoprolol Succinate | 618 | $8,014 |
| Potassium Chloride | 183 | $4,418 |
| Rosuvastatin Calcium | 328 | $4,164 |
| Atorvastatin Calcium | 398 | $3,763 |
| Bumetanide | 43 | $3,106 |
| Carvedilol | 318 | $2,447 |
| Ezetimibe | 115 | $2,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $66 | $60,10858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Colorado Springs
- Deborah JalowiecColorado Springs$106K
- Preetham ReddyColorado Springs$9K
- James MillerColorado Springs$6K
- Kimberly DulaneyColorado Springs$6K
- Brian MetzColorado Springs$6K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Jeffrey BooneGreenwood Village$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.